iLite® ADCP Effector FcγRIIa
BM5004
This iLite® effector cell line enables accurate measurement of ADCP activity via FcγRIIa engagement, supporting bioanalytical studies of monoclonal antibodies.
- High sensitivity and large dynamic range
- "Assay-ready" format for rapid and convenient use
- Reproducible and biologically relevant results
- Reduced assay variability and higher reproducibility compared to cells in culture
- Normalization of cell counts and serum matrix effects using a second reporter gene
Product Overview
iLite® ADCP Effector FcγRIIa Assay Ready Cells are used for quantifying biological activity induced by pathway activation of therapeutic antibody drugs in an ADCP mechanism of action (MOA) assay.
The cells are based on a human T lymphocyte cell line, Jurkat (ATCC #TIB-152), and have been genetically engineered and optimized to express human FcγRIIa-H (the high-affinity H131 variant), and the Firefly Luciferase (FL) reporter gene under the control of a proprietary chimeric promoter.
iLite® ADCP Effector FcγRIIa Assay Ready Cells are ideally matched to the iLite® ADCP target cells but can be run with any type of target cells inducing ADCP MOA.
The ATCC® TIB-152 cell line is used under a license from ATCC
How it works
Principle of iLite® ADCP Bioassays
Our two-cell ADCP bioassays consist of target cells expressing the antigen under study and effector cells closely resembling the natural FcγRIIa (CD32a) signal transduction pathway. Target control cells that do not express the antigen are also available. The effector cells contain two luciferase genes: an inducible Firefly luciferase gene and a constitutively expressed Renilla luciferase gene used for control purposes.
What's in the box?
>250 µL of iLite® Assay Ready Cells suspended in cryoprotective medium.
Specifications
| Product code | BM5004 |
| Assay target | ADCP |
| Technology | Cell-based reporter gene assay |
| Detection system | Luminescence |
| Regulatory status | Research Use Only |
Documents
Application Note
